Endocrinology Advisor13h
Vykat XR Approved to Treat Hyperphagia in Prader-Willi Syndrome
The FDA has approved Vykat XR (diazoxide choline) for the treatment of hyperphagia in adults and pediatric patients 4 years ...
"My daughter struggles with the same rare condition as Katie Price’s son - this is what life is like for us"
A new drug could change everything for children like seven-year-old daughter, Liliana, who has Prader-Willi syndrome, a rare ...
PharmExec5d
FDA Approves Soleno Therapeutics’ Vykat XR for Hyperphagia in Patients with Prader-Willi Syndrome
Approval of Vykat XR marks the first treatment indicated for hyperphagia in patients with Prader-Willi syndrome.
TipRanks on MSN3d
Soleno Therapeutics Stock (SLNO) Surges on FDA Green Light for PWS Treatment
Soleno Therapeutics ($SLNO) stock skyrocketed up over 42% this past week on news that it has achieved a significant milestone ...
STAT6d
NIH director targets misinformation research as more turmoil rocks health agencies
Under the new collaboration, OpenFold will produce a fine-tuned version of its model that’s trained on AbbVie and Johnson & ...
Managed Healthcare Executive5d
FDA Approves First Drug for Excess Hunger in Prader-Willi Syndrome
Vykat XR will be available in April to treat the intense hunger that is a hallmark of the rare genetic disease Prader-Willi ...
Explore more
US FDA Approves First Treatment for Rare Genetic Disorder Prader-Willi Syndrome
(Reuters) -The U.S. Food and Drug Administration on Wednesday approved Soleno Therapeutics' drug to treat a rare genetic ...
PMLive6d
FDA approves Soleno’s Vykat XR as first treatment for hyperphagia in Prader-Willi syndrome
The US Food and Drug Administration (FDA) has approved Soleno Therapeutics’ Vykat XR (diazoxide choline) extended-release ...
Soleno Therapeutics Announces U.S. FDA Approval of VYKATTM XR to Treat Hyperphagia in Prader-Willi Syndrome
First approved therapy to address hyperphagia in individuals with Prader-Willi syndromeManagement to host conference call and webcast today, ...
Disability Scoop5d
FDA Green-Lights First Treatment For Prader-Willi Syndrome
Federal regulators are clearing a first-of-its-kind treatment for symptoms of a rare neurodevelopmental disorder that is ...
Soleno Shares Are Up Today: What's Going On?
Soleno Therapeutics, Inc. (NASDAQ: SLNO) shares are trading higher Thursday after the company announced it secured FDA ...
Monthly Prescribing Reference5d
Vykat XR Approved to Treat Hyperphagia in Prader-Willi Syndrome
Credit: Solano Therapeutics. Vykat XR contains an extended-release formulation of diazoxide choline, the crystalline salt of diazoxide. Vykat XR is expected to be available in April 2025.